Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4665 - Additive effect of Vinca Alkaloids as the Risk Factor for Hearing Impairments in the Childhood Cancer Survivors


10 Sep 2017


Poster display session


Lily Myung-Jin Cha


Annals of Oncology (2017) 28 (suppl_5): v543-v567. 10.1093/annonc/mdx388


L.M. Cha1, M. Huh1, J.Y. Lim2, S.M. Hahn2, C.J. Lyu2, J.W. Han1

Author affiliations

  • 1 Department Of Pediatric Hemato-oncology, Yonsei Cancer Center, 03722 - SEOUL/KR
  • 2 Department Of Pediatric Hemato-oncology, Yonsei Cancer Center, SEOUL/KR


Abstract 4665


The survival rate of childhood cancer is approaching to over 80%, and survivorship is gathering more attention. The survivors receive chemotherapy, radiotherapy and surgery in their early life stages, and the risk of ototoxicity is increased. We evaluated the degree of risk of the clinical factors causing the ototoxicy, in childhood cancer survivors.


We established survivorship program for late effects in Yonsei Cancer Center, Seoul, Korea. In all 531 enrolled survivors in the clinic, 105 patients were invited to evaluate otoxocitity in their bi-annual visits and the clinical risk factors were reviewed retrospectively.


The median age at diagnosis was 6.0 (0∼26). Most common diagnosis was leukemia/lymphoma (N = 30, 30%), and brain tumor was the next (N = 29, 29%). Platinum agents were used in 64%, alkylating agents was in 83% and vinca alkaloid was in 78%. Severe hearing impairments defined as over than 60 dB loss were observed in 37% of left ears and 39% of right ears. The proportion of the survivors who had 20 dB loss in any side of ears was 28%. The 69% of abdomen tumor survivors and 56% of brain tumors had any of hearing impairments, but only 28% of leukemia/lymphoma survivors showed hearing loss (P 


Hearing impairments were common late effects in childhood cancer survivors, and vinca alkaloids had additive adverse effects on the platinum use for the hearing loss.

Clinical trial identification

Legal entity responsible for the study

Jung Woo Han




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.